cemiplimab
sanofi,regeneron
['cemiplimab']
#esmo22
neoadjuvant cemiplimab results for resectable cutaneous scc presented by pcr 50.6%
mpr 12.7%
combined rate 63.3% the trial was simultaneously published in #medtwitter 
MD, Medical Oncologist.
Scientific progress begins with questioning.  Don't be afraid to ask!
#HealthForAll